Stem Cell Transplantation in Head and Neck Cancer: Combining Cancer Treatment With Facial Reconstruction

Table of Contents

• Key Points
• Background: Why This Research Matters
• How This Review Was Conducted
• Stem Cell Biology: The Building Blocks of Regeneration
• Mesenchymal Stem Cells: The Workhorses of Reconstruction
• Induced Pluripotent Stem Cells: A Personalized Approach
• Tissue-Specific Progenitors: Rebuilding Salivary Glands
• How the Tissue Environment Affects Stem Cell Behavior
• Cancer Safety: The Critical Concern
• Cancer Stem Cells and Shared Molecular Pathways
• What Clinical Evidence Exists So Far
• Reconstructive and Regenerative Considerations
• Clinical Implications for Patients
• Limitations of This Review
• Recommendations and Future Directions
• Frequently Asked Questions
• Source Information

Key Points

• Stem cell transplantation for head and neck cancer reconstruction is largely experimental and not yet standard of care for most patients.
• Early studies of a patient's own mesenchymal stem cells for radiation complications showed no increased recurrence up to three years, but long-term data are limited.
• Normal stem cells and cancer stem cells share signaling pathways, so regenerative therapies require careful monitoring for potential tumor-promoting effects.
• Most researchers recommend harvesting a patient's cells before radiotherapy and reinfusing after confirmed remission to reduce tumor contact.
• Systematic monitoring, standardized registries, and molecular profiling of both host tissue and cells are recommended before transplantation.

Background: Why This Research Matters

Head and neck cancers are aggressive tumors that grow in complex anatomical locations. According to epidemiological studies cited in this review, these cancers accounted for more than 800,000 new cases and approximately 500,000 deaths worldwide in 2017.

Despite advances in cancer surgery, radiation therapy, and systemic treatments, survival rates remain limited. This is especially true for patients with advanced or recurring disease. Radical surgical removal of these tumors often requires removing essential functional and aesthetic features of the face and neck.

The consequences for patients are significant. They may lose the ability to speak, swallow, or make facial expressions normally. Quality of life diminishes considerably. Reconstruction of this area must therefore address both physical appearance and functional rehabilitation.

In this context, regenerative medicine — particularly stem cell-based transplantation — has emerged as a potential complement to standard cancer treatment. The goal is to connect oncologic treatment with biological reconstruction.

Stem cells possess distinctive abilities for self-renewal, multilineage differentiation (the capacity to become different cell types), and immunomodulation (regulation of the immune system). These properties allow stem cells to restore tissue balance in the challenging conditions that exist after cancer treatment.

How This Review Was Conducted

This is a narrative minireview, which means the author deliberately chose an interpretive approach rather than a systematic one. The goal was to provide a comprehensive, concept-oriented discussion of diverse literature.

The review covers fundamental stem cell biology, principles of tissue engineering, preclinical models, and new clinical applications in cancer reconstruction. This methodological approach allowed critical contextualization of biological mechanisms, reconstructive techniques, and cancer safety considerations.

Literature was identified through targeted searches of PubMed and Scopus databases. The search covered publications from January 2015 to June 2025. Keywords included stem cells, head and neck cancer, regenerative medicine, tissue engineering, salivary gland repair, and maxillofacial reconstruction.

Studies were selected based on their relevance to the narrative objectives rather than predetermined inclusion or exclusion criteria. The author analyzed clinical investigations, translational research, preclinical models, and authoritative reviews. Data extraction focused on stem cell origin, regenerative applications, integration with cancer therapies, and documented safety issues.

Stem Cell Biology: The Building Blocks of Regeneration

Stem cells are undifferentiated cells that can self-renew and differentiate into several lineages. They serve as the basis for tissue maintenance and regeneration throughout an organism's life.

Stem cells are classified into three main categories based on potency and origin:

• Embryonic stem cells — derived from early-stage embryos
• Pluripotent stem cells — can become any cell type in the body
• Adult stem cells — found in various tissues after birth

Research in head and neck oncology has focused on adult and induced pluripotent stem cells. These cell types can be sourced from the patient's own body (autologously) and exhibit immunomodulatory features advantageous for reconstructive purposes.

The biological activity of these cells underlies their translational significance. They can differentiate into needed cell types, migrate to areas of injury, and secrete trophic and angiogenic factors (substances that promote blood vessel growth). These abilities support healing of post-cancer defects in bone, mucosa (the lining of the mouth and throat), and salivary glands.

Stem cells can respond to microenvironmental signals. This enables them to react dynamically to tissue injury or hypoxia (low oxygen levels). They release signaling molecules that facilitate neovascularization (new blood vessel formation), matrix remodeling, and inflammatory modulation.

Mesenchymal Stem Cells: The Workhorses of Reconstruction

Mesenchymal stem cells (MSCs) have emerged as a fundamental component of regenerative approaches in maxillofacial and reconstructive oncology. MSCs are multipotent adult progenitors that can be extracted from several sources.

Each source has distinct differentiation potentials and paracrine profiles (the mix of signaling molecules they release):

• Bone marrow-derived MSCs — the first to be identified and most thoroughly characterized; they have significant osteogenic (bone-forming) and chondrogenic (cartilage-forming) capabilities, making them especially appropriate for skeletal restoration
• Adipose-derived MSCs — advantageous due to their abundance and less invasive extraction; they demonstrate superior soft-tissue regeneration potential through release of vascular endothelial growth factor (VEGF), fibroblast growth factor, and interleukin-10
• Dental pulp and periodontal ligament MSCs — particularly advantageous for craniofacial applications due to their embryological resemblance to neural crest-derived tissues in the head and neck, which enhances their ability for dentin and neural repair

In vitro investigations (studies performed in laboratory dishes) reveal that all MSC subtypes can differentiate into osteogenic and epithelial lineages. This occurs when they are exposed to local growth factors, including bone morphogenetic protein-2 and transforming growth factor-β (TGF-β). These factors are prevalent in irradiated or surgical wound environments.

The paracrine function of MSCs is widely acknowledged as the primary factor influencing their regenerative effectiveness, rather than mere direct differentiation. MSCs promote healing in irradiated tissues by secreting cytokines, chemokines, and extracellular vesicles that exert anti-inflammatory and immunoregulatory effects.

Their exosomes (tiny particles released from cells) contain microRNAs and proteins that inhibit apoptosis (programmed cell death), promote endothelial proliferation, and regulate extracellular matrix deposition. In head and neck reconstruction, these signaling systems facilitate increased vascularization of flaps and grafts, promote enhanced wound healing, and mitigate fibrosis after radiotherapy.

Moreover, MSCs engage with local immune cells. They can transform macrophages from pro-inflammatory M1 to reparative M2 phenotypes and attenuate T-cell cytotoxicity. These immunomodulatory characteristics make them optimal candidates for reconstructive treatments characterized by significant inflammation and ischemia (restricted blood supply).

However, this immunological interaction requires careful monitoring. Similar processes may affect tumor-associated immune evasion, highlighting the fragile equilibrium between regeneration and cancer safety.

Induced Pluripotent Stem Cells: A Personalized Approach

Induced pluripotent stem cells (iPSCs) have broadened opportunities for patient-specific restorative treatments. iPSCs are produced by converting somatic cells (ordinary body cells) into an embryonic-like state.

These cells have the theoretical capability to develop into any cell lineage. This offers an inexhaustible autologous supply for craniofacial tissue engineering. Their application in head and neck contexts has encompassed differentiation into osteoblasts, chondrocytes, and salivary gland acinar-like cells, as well as the production of epithelial sheets for mucosal healing.

The pluripotent characteristics of iPSCs provide unparalleled versatility. However, their therapeutic application is limited by several concerns:

• Genomic instability (changes in DNA that could cause problems)
• Epigenetic memory (retention of characteristics from the original cell type)
• Risk of tumorigenicity (potential to form tumors)

The concept of iPSCs was first established by Takahashi in 2006-2007. This research demonstrated that differentiated somatic cells could be reprogrammed into a pluripotent state by enforced expression of specific transcription factors. This discovery signifies a paradigm shift in regenerative biology.

It enables the creation of patient-specific pluripotent cells without the ethical issues associated with embryonic stem cells. Current research seeks to alleviate safety concerns by employing integration-free reprogramming techniques and pre-differentiation processes that diminish the remaining pluripotent cell populations.

Notwithstanding these obstacles, iPSCs provide potential for the reconstruction of intricate composite structures in the craniofacial area. This is particularly promising when integrated with three-dimensional bioprinting and scaffold-guided development.

Tissue-Specific Progenitors: Rebuilding Salivary Glands

A unique yet therapeutically relevant stem cell population in this domain comprises tissue-specific progenitor cells, including those derived from salivary glands. These cells have demonstrated the ability to rebuild glandular tissue following radiation-induced damage.

Evidence comes from both animal models and preliminary clinical investigations. By separating c-Kit-positive progenitors and reinfusing them after therapy, researchers accomplished partial restoration of salivary flow and histological recovery of acinar structures.

These findings demonstrate that organ-specific stem cells can regenerate specialized tissues damaged by cancer treatment. This offers a targeted regenerative approach distinct from general mesenchymal or pluripotent approaches.

Future investigations seek to enhance harvesting and cultivation techniques. Researchers also aim to incorporate these cells into biocompatible hydrogels and establish standardized protocols for autologous transplantation.

How the Tissue Environment Affects Stem Cell Behavior

The tumor microenvironment significantly impacts stem cell behavior. It determines whether reparative or pathogenic (disease-promoting) pathways dominate.

Hypoxia, inflammation, and oxidative stress are prevalent characteristics of post-radiation tissue. These conditions regulate stem cell viability and differentiation.

Experimental findings indicate that preconditioning MSCs with hypoxia or inflammatory cytokines improves their survival and angiogenic potential. This occurs when the cells are transplanted into ischemic organs.

In contrast, continuous exposure to oncogenic signaling molecules may modify MSC phenotype to a more fibroblastic or pro-angiogenic profile. This could potentially promote tumor growth.

Comprehending and managing this crosstalk is crucial for guaranteeing therapeutic safety. The nascent discipline of "cancer-educated" stromal biology aims to identify molecular switches. These switches might dissociate regenerative functions from tumor-promoting effects, facilitating safer implementation of stem cell-based reconstruction in oncology.

The fundamental basis of stem cell therapy in head and neck oncology lies in their distinctive differentiation capacity, paracrine signaling, and immunomodulatory effects. MSCs, iPSCs, and tissue-specific progenitors may have unique advantages tailored to various reconstructive problems. These range from bone and cartilage regeneration to glandular and mucosal tissue restoration.

Stem cells can exhibit duality: They can promote or inhibit tumor growth and contribute to therapeutic resistance. A comprehensive understanding of stem cell biology is essential for clinicians and researchers aiming to integrate regenerative technology with cancer reconstruction to optimize safety and therapeutic efficacy.

Cancer Safety: The Critical Concern

The incorporation of stem cell transplantation into head and neck oncology necessitates a thorough comprehension of its possible interactions with tumor biology. Head and neck squamous cell carcinoma (HNSCC) is characterized by significant heterogeneity, frequent recurrence, and the presence of cell subpopulations exhibiting stem-like characteristics.

These cells are known as cancer stem cells (CSCs). They demonstrate self-renewal, quiescence (dormancy), and pluripotent differentiation abilities. These properties render them resistant to standard chemotherapy and radiotherapy.

CSCs are characterized by the presence of distinct markers, including:

• CD44
• Aldehyde dehydrogenase 1
• SRY-box 2
• Octamer-binding transcription factor 4
• NANOG

These markers are associated with increased metastatic activity and treatment resistance. The presence of these cell subsets significantly impacts the safety of regenerative methods. External stem cell transplantation could affect CSC habitats or signaling pathways that support tumor survival.

Comprehending the interaction between transplanted or mobilized stem cells and residual malignant or pre-malignant cells is essential before implementing these therapies in clinical oncology.

Cancer Stem Cells and Shared Molecular Pathways

At the molecular level, CSCs and normal stem cells share overlapping signaling pathways that govern self-renewal and differentiation. These include:

• Wnt/β-catenin pathway
• Notch pathway
• Hedgehog pathway
• Phosphatidylinositol 3-kinase-protein kinase B pathway

The common pathways highlight a potential risk. Regenerative stem cell therapies could unintentionally trigger pro-tumorigenic processes in previously treated tissues.

The stimulation of the Wnt/β-catenin pathway, which facilitates MSC osteogenesis, also plays a role in epithelial-mesenchymal transition and invasion in HNSCC. Notch signaling serves multiple functions — facilitating differentiation under normal circumstances while increasing tumorigenicity when dysregulated.

Research with animals has shown that MSCs can have both anticancer and protumor effects. These effects are influenced by the microenvironment, dosage, and manner of delivery.

In certain models, MSCs express molecules such as interleukin-10, TGF-β, and prostaglandin E2 that suppress inflammation and tumor progression. Conversely, in other models, they release VEGF and matrix metalloproteinases that promote angiogenesis and metastasis.

The dual nature of MSCs underscores the necessity of regulating their differentiation state and microenvironmental conditions. This is required to avert inadvertent oncogenic activation.

What Clinical Evidence Exists So Far

There is limited information on cancer safety in patients who have undergone stem cell therapy after cancer treatment. Initial investigations examining autologous MSCs for osteoradionecrosis or radiation-induced xerostomia have not indicated elevated recurrence rates.

These follow-up periods extend up to three years. However, long-term oncological data are limited, and sample sizes are inadequate to exclude infrequent adverse occurrences.

In contrast, hematopoietic stem cell transplantation (transplantation of blood-forming stem cells) is linked to a heightened risk of secondary malignancies. This indicates that extended immunosuppression or genomic instability may predispose individuals to carcinogenesis (cancer development).

Although the mechanisms in regenerative cell treatment differ from hematopoietic stem cell transplantation, these findings underscore the necessity for systematic monitoring and standardized registries. Such registries would record outcomes beyond immediate repair.

The timing of stem cell application is critical. Most researchers advocate autologous cell harvest before radiotherapy and reinfusion after the completion of cancer treatment, once disease remission is verified. This method reduces the likelihood of tumor-stromal contact and offers a safer therapeutic margin for regenerative interventions.

Another oncological issue is the microenvironmental alteration of irradiated or surgically modified tissues. Radiation fibrosis and persistent inflammation can establish a pro-angiogenic and immunosuppressive environment that may influence the outcome of transplanted cells.

Research indicates that irradiated tissues exhibit increased levels of stromal-derived factor 1. This attracts circulating progenitor cells, potentially affecting both regenerative and malignant mechanisms. The dual recruitment effect underscores the need to delineate the molecular profile of recipient tissues prior to cell transplantation.

Moreover, immunomodulation elicited by MSCs may hinder anticancer immune surveillance. This occurs by suppressing the activity of cytotoxic T cells and NK cells. These processes, although advantageous for diminishing inflammation, could conceivably enable immune evasion of remaining malignant cells.

Consequently, forthcoming clinical protocols must incorporate molecular profiling of both the host environment and the treated cell populations. Stringent preclinical models evaluating dosage, delivery route, and interactions with cancer medicines are also needed.

The oncological ramifications of stem cell treatment in head and neck cancer are complex. Although existing clinical findings are encouraging in the near term, the molecular similarities between normal stem cells and CSCs require careful interpretation and long-term surveillance.

Comprehending and regulating stem cell signaling, optimizing therapy sequences, and integrating molecular surveillance are crucial to reduce the likelihood of tumor recurrence. As regenerative medicine advances towards clinical integration in cancer, the primary problem directing translational research and ethical application is reconciling the regenerative advantages of stem cell transplantation with cancer safety.

Reconstructive and Regenerative Considerations

The conceptual basis of tissue engineering is conventionally characterized as a triad including three interrelated components:

1. Cells — confer regenerative capacity
2. Scaffolds — furnish a three-dimensional structural framework that directs tissue development
3. Biological signaling factors — govern cell viability, differentiation, and spatial arrangement

In head and neck oncology, this paradigm is particularly pertinent. Intricate composite abnormalities necessitate synchronized regeneration of osseous (bone), soft tissue, and vascular components. Stem cells constitute the biological element of this triad.

Autologous and allogeneic stem cell-based approaches (using the patient's own cells or cells from a donor) are often combined with bioengineered scaffolds. These combinations have been shown to improve vascularization and functional restoration in complex craniofacial structures.

In mandibular osteoradionecrosis (bone death in the lower jaw after radiation), MSCs combined with bioengineered scaffolds have resulted in bone regeneration and enhanced functional outcomes. This indicates a synergistic effect in reconstructive surgery.

These findings highlight the viability of biologically driven reconstruction. Such approaches enhance conventional cancer therapy while reducing donor site morbidity (complications at the site where tissue is harvested).

Clinical Implications for Patients

Stem cell transplantation in head and neck oncology represents a promising advancement. It integrates cancer treatment with regenerative reconstruction.

Clinicians want to restore form and function after cancer excision by utilizing the biological plasticity of stem cells while avoiding consequences. The field includes innovative methods in bone and soft tissue regeneration, immunomodulation, and integration with surgical reconstruction.

This presents the possibility of transforming traditional cancer treatment into a holistic, restorative, and patient-focused strategy. The goal shifts from survival-focused care to holistic oncological and functional rehabilitation.

For patients, this means the potential for:

• Improved vascularization of reconstructed tissues
• Expedited osseointegration (integration of implants with bone)
• Facilitated salivary gland healing after radiation injury
• Enhanced functional restoration in complex craniofacial structures
• Reduced donor site morbidity compared to traditional reconstruction

However, patients should understand that these approaches remain largely experimental. They are not yet standard of care for most head and neck cancer patients.

Limitations of This Review

This is a narrative review, not a systematic review. The author deliberately chose this approach to provide a comprehensive, concept-oriented discussion rather than a quantitative analysis.

Several important limitations exist in the current evidence base:

• Limited long-term safety data — Most clinical studies have follow-up periods of only up to three years
• Small sample sizes — Current studies are inadequate to exclude infrequent adverse occurrences
• Lack of standardized protocols — No consensus exists on optimal cell types, dosages, or delivery methods
• Regulatory and ethical barriers — These prevent widespread use of stem cell-based therapies in clinical oncology
• Scientific uncertainties — Concerns persist about tumor recurrence, stem cell plasticity, and carcinogenic dangers of introducing stem cell-derived materials into previously treated or irradiated areas

The review also acknowledges that the molecular similarities between normal stem cells and cancer stem cells require careful interpretation. The dual nature of MSCs — with both anticancer and protumor effects depending on context — underscores the complexity of this field.

Recommendations and Future Directions

Stem cell-centered research can transform head and neck cancer treatment. The goal is to move from survival-focused care to holistic oncological and functional rehabilitation that improves both lifespan and quality of life.

Several key recommendations emerge from this review:

1. Systematic monitoring and standardized registries — These are needed to record outcomes beyond immediate repair and track long-term safety
2. Molecular profiling — Both the host environment and treated cell populations should be profiled before transplantation
3. Optimized timing — Autologous cell harvest before radiotherapy and reinfusion after verified disease remission appears safest
4. Stringent preclinical models — These should evaluate dosage, delivery route, and interactions with cancer medicines
5. Integration with precision surgery — Regenerative science should be combined with precision surgical techniques

Future investigations seek to enhance harvesting and cultivation techniques for tissue-specific progenitors. Researchers also aim to incorporate these cells into biocompatible hydrogels and establish standardized protocols for autologous transplantation.

The nascent discipline of "cancer-educated" stromal biology aims to identify molecular switches. These switches might dissociate regenerative functions from tumor-promoting effects, facilitating safer implementation of stem cell-based reconstruction in oncology.

As regenerative medicine advances towards clinical integration in cancer, the primary challenge is reconciling the regenerative advantages of stem cell transplantation with oncologic safety. This balance will direct translational research and ethical application in the coming years.

Frequently Asked Questions

What are stem cells, and how might they help after head and neck cancer treatment?

Stem cells are undifferentiated cells that can self-renew and become several cell types. In head and neck cancer, research focuses on adult and induced pluripotent stem cells, usually taken from the patient. They may help rebuild bone, soft tissue, and salivary glands after tumor removal or radiation, mainly by releasing signaling molecules that support healing.

Are stem cell treatments for head and neck cancer currently standard care?

No. These approaches remain largely experimental and are not yet standard of care for most patients with head and neck cancer. Current evidence comes from early clinical studies, animal models, and laboratory work. If you are considering stem cell therapy, discuss it with your oncology team as part of a clinical trial or carefully monitored program.

What does the evidence say about cancer recurrence after stem cell therapy?

Initial studies of a patient's own mesenchymal stem cells for osteoradionecrosis or radiation-induced dry mouth have not shown increased recurrence during follow-up up to three years. However, long-term safety data are limited, and sample sizes are too small to rule out rare adverse events. Systematic monitoring and standardized registries are recommended.

What are the main safety concerns with stem cell transplantation in cancer patients?

Normal stem cells and cancer stem cells share signaling pathways, such as Wnt, Notch, Hedgehog, and PI3K-Akt. This overlap means regenerative therapies could unintentionally activate tumor-promoting processes. Mesenchymal stem cells can also suppress some immune surveillance. Long-term safety data are limited, so careful monitoring and molecular profiling are needed before transplantation.

How is the timing of stem cell harvest and reinfusion planned?

Most researchers suggest collecting a patient's own cells before radiotherapy and reinfusing them after cancer treatment is complete and disease remission is confirmed. This approach reduces contact between transplanted cells and any remaining tumor cells, offering a safer margin for regenerative interventions. Timing is considered critical for both safety and effectiveness.

What types of stem cells are being studied for head and neck reconstruction?

Research focuses on mesenchymal stem cells from bone marrow, fat, dental pulp, and periodontal ligament; induced pluripotent stem cells; and tissue-specific progenitors such as salivary gland cells. Each type has distinct properties. For example, bone marrow MSCs are well studied for bone formation, while salivary progenitors have partially restored salivary flow in early work.

What are the limitations of the current evidence on stem cell therapy for head and neck cancer?

Most clinical studies have follow-up of only up to three years, and sample sizes are too small to detect rare adverse events. There is no consensus on optimal cell types, doses, or delivery methods. Regulatory and ethical barriers also limit widespread use. Scientific uncertainties remain about tumor recurrence and the behavior of stem cell-derived materials in irradiated tissue.

If I have head and neck cancer and my team recommends stem cell transplantation with facial reconstruction, when should I get a second opinion?

Stem cell-based reconstruction after head and neck cancer surgery remains largely experimental and is not standard of care for most patients. A second opinion is reasonable before committing, because no consensus exists on optimal cell types, dosages, or delivery methods, and long-term safety data are limited, with most studies following patients only up to three years. An independent review can examine whether the proposed timing, cell source, and reconstructive plan fit your situation, and whether molecular profiling of the treated tissue has been considered. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original Article Title: Stem cell transplantation in head and neck oncology: Integrating oncologic treatment and maxillofacial reconstruction.

DOI: 10.5500/wjt.v16.i2.117675

License: CC BY-NC (open access)

Authors: Zeppieri M, Capobianco M, Visalli F, Khouyyi M, Gagliano C, Cappellani F, Robiony M, Tel A, Michelutti L.

Journal: World Journal of Transplantation

Publication Details: Volume 16, Issue 2, Article 117675. Published online June 18, 2026.

DOI: 10.5500/wjt.v16.i2.117675

Article Type: Minireview (peer-reviewed)

Corresponding Author: Marco Zeppieri, Department of Ophthalmology, University Hospital of Udine, Italy

This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace consultation with qualified healthcare providers. Patients considering stem cell therapies should discuss all treatment options with their oncology team.